These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10265100)

  • 1. The role of the innovation-based pharmaceutical industry in international drug information communication.
    Hoff LC
    Drug Inf J; 1983; 17(4):271-6. PubMed ID: 10265100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Communicating a drug alert. A case study on acitretin in The Netherlands.
    Sturkenboom MC; de Jong-van den Berg LT; Cornel MC; Stricker BH; Wesseling H
    Eur J Clin Pharmacol; 1994; 47(2):125-32. PubMed ID: 7859798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Providing drug information to health professionals and consumers: role and responsibility of the pharmaceutical manufacturer.
    Boyland JI
    Hosp Pharm; 1983 Apr; 18(4):211-3, 216. PubMed ID: 10260207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of services provided by pharmaceutical companies: perceptions of physicians and pharmaceutical sales representatives.
    Gaedeke RM; Tootelian DH; Sanders EE
    Health Mark Q; 1999; 17(1):23-31. PubMed ID: 11066720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timeliness of receipt of manufacturers' new product information.
    Murdoch LA; Lum L
    Can J Hosp Pharm; 1991 Oct; 44(5):235-8. PubMed ID: 10115576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanics of assembling an international drug dossier.
    Buday PV
    Drug Inf J; 1983; 17(3):133-8. PubMed ID: 10265093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.
    Tyrawski J; DeAndrea DC
    J Med Internet Res; 2015 Jun; 17(6):e130. PubMed ID: 26032738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsiveness to physicians' requests for information concerning drug interactions: a comparison of brand and generic companies.
    Thomas M; Lexchin J
    Soc Sci Med; 1990; 31(2):153-7. PubMed ID: 2389150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secrecy and transparency of medicines licensing in the EU.
    Abraham J; Lewis G
    Lancet; 1998 Aug; 352(9126):480-2. PubMed ID: 9708771
    [No Abstract]   [Full Text] [Related]  

  • 12. Information on marketed drugs for doctors and patients. Experience in six European countries.
    Brown P; Charlish P; Brazier H; Butterfield M
    Int J Technol Assess Health Care; 1995; 11(3):410-6. PubMed ID: 7591543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Early achievements of the Danish pharmaceutical industry-6 Pharmacia].
    Grevsen JV; Kruse E; Kruse PR
    Theriaca; 2014; (42):9-30. PubMed ID: 25816560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug use in academic medical centres in an era of ferment.
    Avorn J
    Pharmacoeconomics; 1996; 10 Suppl 2():124-9. PubMed ID: 10163429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of drug information service provided by pharmaceutical manufacturers.
    Doyal LE
    Am J Hosp Pharm; 1990 May; 47(5):1014. PubMed ID: 2337090
    [No Abstract]   [Full Text] [Related]  

  • 17. Validity of information received from pharmaceutical companies.
    Wilson DE; Crabbe SJ
    DICP; 1990 Nov; 24(11):1117. PubMed ID: 2275242
    [No Abstract]   [Full Text] [Related]  

  • 18. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
    Kock M; Thomsen MK
    Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Information from drug companies and opinion leaders.
    Liberati A; Magrini N
    BMJ; 2003 May; 326(7400):1156-7. PubMed ID: 12775588
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.